Evolution of Systemic Treatment Uptake and Survival in Advanced Non-Small Cell Lung Cancer

Background: Non-small cell lung cancer (NSCLC) commonly presents at advanced stage. We previously reported systemic treatment uptake in stage IV NSCLC climbing from 55% (2009–2012) to 62% (2015–2017). Since then, first-line immunotherapy and 2nd/3rd generation tyrosine kinase inhibitors (TKIs) have...

Descripció completa

Dades bibliogràfiques

Autors principals:	Sophie Stock-Martineau, Katie Laurie, Mathieu McKinnon, Tinghua Zhang, Paul Wheatley-Price
Format:	Artigo
Idioma:	Inglês
Publicat:	MDPI AG 2020-12-01
Col·lecció:	Current Oncology
Matèries:	non-small-cell lung cancer real-world data chemotherapy epidermal growth factor receptor anaplastic lymphoma kinase immune checkpoint inhibitor
Accés en línia:	https://www.mdpi.com/1718-7729/28/1/8
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!